{"type":"trials","record":{"id":42055,"source_id":"clinicaltrials-gov","external_id":"NCT06184360","title":"Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)","brief_summary":"This was a retrospective, observational cohort study. Data were analyzed from the Intelligent Research in Sight (IRIS) registry from October 8, 2019, through November 26, 2021, with a follow-up period of 12 months following the first brolucizumab injection (index date).","overall_status":"Completed","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Novartis Pharmaceuticals","enrollment":2079,"countries":["United States"],"start_date":"2022-05-31","completion_date":"2022-12-16","last_update_date":"2023-12-28","source_url":"https://clinicaltrials.gov/study/NCT06184360","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"18 Years","comparator":null,"organization":"Novartis","interventions":[],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in Best Recorded Visual Acuity, Stratified by Prior Treatment Status — Baseline up to 12 months","Change in Injection Interval at 12 Months of Brolucizumab Treatment Compared with Prior Anti-vascular Endothelial Growt…","Number of eyes with adverse events — Baseline up to 12 months","Time to adverse event — Baseline up to 12 months","Number of brolucizumab injections prior to adverse event — Baseline up to 12 months","Brolucizumab Injection Interval and Interval Extension, Stratified by Pre-Switch Interval — Baseline up to 12 months"],"design_description":null,"source_has_results":false},"controlled_terms":["Neovascular (Wet) Age-related Macular Degeneration"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06184360","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-05-31 to 2022-12-16","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.913Z","intervention":[],"participants":2079,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in Best Recorded Visual Acuity, Stratified by Prior Treatment Status — Baseline up to 12 months","Change in Injection Interval at 12 Months of Brolucizumab Treatment Compared with Prior Anti-vascular Endothelial Growt…","Number of eyes with adverse events — Baseline up to 12 months","Time to adverse event — Baseline up to 12 months","Number of brolucizumab injections prior to adverse event — Baseline up to 12 months","Brolucizumab Injection Interval and Interval Extension, Stratified by Pre-Switch Interval — Baseline up to 12 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42055","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}